2024-519637-32-00Not yet recruitingPhase 2
Effect of Cannabidiol on Muscle Mass and Mitochondrial Function in Head and Neck Cancer
PANACEA : Effect of PrehAbilitation by NutritionAl supplementation with Cannabidiol on skeletal muscle mass and mitochondrial function in hEad and neck cAncer : a proof of concept controlled randomized trial
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Jan 2026
Brief summary (registry, in English)
Improvement of muscle health assessed by muscle mitochondrial activity perioperatively by adding cannabidiol (CBD) to nutritional supplementation in head and neck cancer
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 27 May 2025
- Start date
- 1 Jun 2025
- Lead sponsor
- University Hospital Of Clermont-Ferrand
- Diseases
- Head and neck cancer
- EU CT number
- 2024-519637-32-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Addiction to other drugs or cannabis
- Malnutrition prior to the onset of head and neck cancer
Other illness
- History of severe heart failure, severe respiratory failure, severe renal failure, severe chronic obstructive pulmonary disease, uncontrolled insulin-dependent diabetes or uncontrolled coronary artery disease
- History of chemotherapy or radiotherapy for head and neck cancer
- History of epilepsy
Age
- Age <18 years
Other
- Pregnant and breastfeeding women
- Persons under curatorship, guardianship, protection of justice or deprived of liberty
- Morbid obesity
- Absence of nutritional risk (grade 1) or severe nutritional risk requiring urgent renutrition (grade 4) during the nutritional assessment
Who the study is looking for
- Squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx, larynx or prevalent lymphadenopathy) or high probability of squamous cell carcinoma of the head and neck according to the judgment of the investigator (without histological confirmation)
- Stage 2 or 3 nutritional risk according to the classification specific to this study (light to moderate nutritional risk)
- Consent to participate in the study
- For women of childbearing age: absence of current pregnancy and effective contraceptive method for the duration of treatment with CBD and up to 7 days after the end of treatment
- To have of a means of communication (mobile phone) to monitor tolerance and appetite while taking CBD
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Of Clermont-Ferrand | Clermont-Ferrand | France | Not yet recruiting |
| Chu Gabriel Montpied | Clermont-Ferrand | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.